Abstract:Abstract Background Ischemic coronary artery disease (CAD) is a major public health problem across the world. Early detection and appropriate management significantly reduced CAD-induced morbidities and death. Endothelial cells are pathogenically implicated. Purpose Our study was designed to investigate the role of the soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) in the in vitro protective effect of Metoprolol against hypoxia-induced injury of Human umbilical vein endothelial cells (HUVECs). Secondly, the clinical significance of variations in serum levels of sLOX-1 in patients with CAD was assessed. Methods In vitro, hypoxic injury model of HUVECs was established in an atmosphere of 1% O2, 95% N2, and 5% CO2 for 24 hours. The protective effect and mechanism of action of the cardio-selective beta-blocker Metoprolol at 10–6 μM concentration was investigated. Consented stable atherosclerotic CAD (n=150) and unstable angina pectoris patients (n=75) along with 150 healthy volunteer subjects were voluntarily enrolled in this ethically approved study. Invasive coronary angiogram with ≥50% stenosis at least in one major coronary artery was used for diagnosis. ESC/ACC/AHC/practical protocols were used for categorizing patients into stable or unstable CAD. Serum sLOX-1 level was measured using specific ELISA kit. The diagnostic significance of serum sLOX-1 levels was assessed by analyzing its area under the curve (AUC). Results In vitro hypoxic conditions induced high rate of cellular apoptosis, high levels of LOX-1 expression, reactive oxygen species (ROS) generation and LDH release from HUVECs after 24 hours incubation, compared to normoxic control cells. Metoprolol significantly decreased LOX-1 levels, and prevented the release of LDH and generation of ROS. This culminated into marked improvement in cellular viability of hypoxia-exposed HUVECs (p<0.001). Compared to healthy subjects, serum levels of sLOX-1s were significantly elevated in atherosclerotic stable and unstable CAD patients (p<0.001). Serum sLOX-1 levels were increased by 4.21 folds in stable CAD patients and by 6.373 folds in atherosclerotic unstable angina patients vs. healthy participants. Moreover, the levels in the two patients' groups were significantly different (p<0.001). In stable angina CAD patients, sLOX-1 AUC = 0.929; and in unstable CAD patients, AUC = 0.944, indicating that serum sLOX-1 levels clearly differentiated patients from healthy participants with high specificity and sensitivity. Conclusions Extrapolated from HUVECs hypoxia-induced injury model and the protective effect of Metoprolol, elevation of the circulating levels of sLOX-1 correlated with increased risks for atherosclerotic CAD and is a highly sensitive and specific biomarker for early detection of the disease. Funding Acknowledgement Type of funding source: None

Association Between Impaired Cutaneous Microvascular Endothelial Function and Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Patients with Coronary Slow Flow

Estimating Current and Long-Term Risks of Coronary Artery in Silico by Fractional Flow Reserve, Wall Shear Stress and Low-Density Lipoprotein Filtration Rate

[Value of Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1) and LOX-1 Mrna in Peripheral Mononuclear Cells in Early Diagnosis of Acute Coronary Syndrome].

Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow

[Clinical and Angiographic Characteristics of Patients with Slow Coronary Flow].

Analysis of correlative factors of female coronary slow-flow phenomenon: A retrospective study

The Relationship Between Myocardial Perfusion and Left Ventricular Longitudinal Systolic Function in Patients with Coronary Slow Flow

Biophysical characterization of a beta-peptide bundle: comparison to natural proteins.

Association Between Systemic Inflammation Response Index and Slow Coronary Flow Phenomenon in Patients with Ischemia and No Obstructive Coronary Arteries

Relationship Between Blood Ox-Ldl Levels in Coronary Sinus and Impaired Endothelium-Dependent Vasodilation in Patients with Coronary Artery Disease

Differential gene expression and miRNA regulatory network in coronary slow flow

Relationship of Soluble Lectin-Like Low-Density Lipoprotein Receptor-1 (sLOX-1) With Inflammation and Coronary Plaque Progression in Psoriasis

Reduced Coupling Between the Global Blood-Oxygen-level-dependent Signal and Cerebrospinal Fluid Inflow is Associated with the Severity of Small Vessel Disease.

Oxidized low-density lipoprotein attenuated desmoglein 1 and desmocollin 2 expression via LOX-1/Ca(2+)/PKC-β signal in human umbilical vein endothelial cells.

Homocysteine levels in patients with coronary slow flow phenomenon: A meta-analysis

Early Assessment of Left Ventricular Function by Layer-Specific Strain and Its Relationship to Pulsatile Arterial Load in Patients with Coronary Slow Flow

The clinical impact of serum sLOX-1 level in coronary artery disease patients as inferred from its implication in the in vitro protective effects of metoprolol against hypoxic injury of HUVECs

Disruption of Interactions between Hydrophobic Residues on Nonpolar Faces is a Key Determinant in Decreasing Hemolysis and Increasing Antimicrobial Activities of α‐Helical Amphipathic Peptides

Reticulated platelets and coronary slow flow: a study in stable coronary artery disease

Plasma atherogenic indices are independent predictors of slow coronary flow

Subclinical myocardial dysfunction in coronary slow flow phenomenon: identification by speckle tracking echocardiography.